Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 344

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

Duvic, Madeleine, Vu, Jenny·2007·Expert Opinion on Investigational Drugs

Abstract

Epigenetic regulation of gene transcription by small-molecule inhibitors of histone deacetylases (HDACs) is a novel cancer therapy. Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in Phase I development. In two Phase II trials, vorinostat 400 mg/day was safe and effective with an overall response rate of 24-30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome. The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543784.16.7.1111

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 56

  1. 10.1056/NEJMra032810 · DOI · Paper page
  2. 10.1111/j.1468-3083.2004.00937.x · DOI · Paper page
  3. 10.1080/10428190410001693560 · doi:10.1080/10428190410001693560
  4. 10.1111/1523-1747.ep12363352 · DOI
  5. 10.1172/JCI200524826 · DOI
  6. BERGER, 2002, Blood, 99, 2929, 10.1182/blood.V99.8.2929 · doi:10.1182/blood.v99.8.2929
  7. 10.1182/blood.V100.9.3369 · DOI
  8. ROOK, 1997, Clin. Exp. Immunol, 107, 16
  9. 10.1182/blood-2006-06-025999 · DOI · Paper page
  10. 10.1111/j.0022-202X.2005.23925.x · DOI · Paper page
  11. 10.1200/JCO.2005.14.167 · DOI · Paper page
  12. 10.1038/sj.bjc.6603465 · DOI
  13. 10.1111/j.1600-0609.2005.00546.x · DOI
  14. 10.1016/j.jmb.2004.02.006 · DOI · Paper page
  15. 10.1186/1741-7007-4-24 · DOI
  16. 10.1146/annurev.biochem.73.011303.073651 · DOI · Paper page
  17. 10.1016/j.jmb.2004.02.006 · DOI · Paper page
  18. FURUMAI, 2002, Cancer Res, 62, 4916
  19. 10.1038/ncponc0106 · DOI · Paper page
  20. O’, 2005, Eur. J. Haematol. Suppl, 150
  21. BUTLER, 2000, Cancer Res, 60, 5165
  22. 10.1073/pnas.182372299 · DOI · Paper page
  23. 10.1002/jcb.20045 · DOI · Paper page
  24. 10.1038/sj.leu.2402535 · DOI · Paper page
  25. 10.1182/blood-2002-08-2675 · DOI · Paper page
  26. 10.1172/JCI200111537 · doi:10.1172/jci200111537 · Paper page
  27. 10.1016/j.exphem.2004.09.008 · DOI
  28. KELLY, 2003, Clin. Cancer Res, 9, 3578
  29. 10.1200/JCO.2005.01.9679 · DOI · Paper page
  30. GARCIA-MANERO, 2005, Blood, 106, 785a, 10.1182/blood.V106.11.785.785 · doi:10.1182/blood.v106.11.785.785
  31. 10.1002/ijc.21939 · DOI
  32. 10.1067/mjd.2002.118538 · DOI · Paper page
  33. 10.1002/ijc.21824 · DOI
  34. 10.1038/sj.onc.1203176 · DOI · Paper page
  35. DESAI, 2003, Anticancer Res, 23, 499
  36. 10.2174/1568011054866946 · DOI
  37. 10.1517/13543784.14.12.1497 · DOI · Paper page
  38. BUTLER, 2000, Cancer Res, 60, 5165
  39. 10.1073/pnas.180316197 · DOI · Paper page
  40. 10.1073/pnas.0307708100 · DOI · Paper page
  41. ROSATO, 2003, Mol. Cancer Ther, 2, 1273
  42. 10.1073/pnas.0408345102 · DOI · Paper page
  43. 10.1158/0008-5472.CAN-03-2629 · DOI · Paper page
  44. 10.1073/pnas.0408732102 · DOI · Paper page
  45. 10.1182/blood-2003-09-3068 · DOI · Paper page
  46. 10.4161/cc.4.4.1564 · DOI
  47. MEI, 2004, Int. J. Oncol, 25, 1509
  48. 10.1016/j.ctrv.2004.04.006 · DOI
  49. 10.1038/sj.leu.2403385 · DOI · Paper page
  50. 10.1517/14728222.8.5.409 · DOI · Paper page
  51. 10.1111/j.1365-2567.2005.02091.x · DOI · Paper page
  52. DUVIC, 2006, Blood, 108, 112a, 10.1182/blood.V108.11.112.112 · doi:10.1182/blood.v108.11.112.112
  53. OLSEN, 2006, ASCO Annual Meeting Proceedings, 24, 7500
  54. 10.1158/1078-0432.CCR-06-2672 · DOI · Paper page
  55. DUVIC, 2001, J. Clin. Oncol, 19, 2456, 10.1200/JCO.2001.19.9.2456 · DOI · Paper page
  56. 10.1038/nrd2133 · DOI · Paper page

Cited by

See all 344

Metadata

Authors
Duvic, M., & Vu, J.
Venue
Expert Opinion on Investigational Drugs
Published
2007-06-26
Volume
16
Issue
7
Pages
1111-1120
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W1968568016
Cited by
344
References
3
FWCI
26.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. https://app.cochat.ai/papers/10.1517/13543784.16.7.1111
The paper
Duvic, M., & Vu, J. (2007). Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.16.7.1111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.